MedTrace Logo

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

NCT04577300 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-11-04

No results posted yet for this study

Summary

To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell therapy (ECT) on visual impairment related to glaucoma.

Conditions

Interventions

DRUG

NT-501

Implant of Neurotech NT-501 device(s)

OTHER

Sham comparator

Sham implantation

Sponsors & Collaborators

Principal Investigators

  • Jeffrey L Goldberg, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2025-08-15
Completion
2026-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577300 on ClinicalTrials.gov